KRD (CARFILZOMIB PLUS LENALIDOMIDE PLUS DEXAMETHASONE) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN CAMPANIA REGION: A ONE-YEAR SURVEY

被引：0
|
作者：
Palmieri, S. [1 ]
Rocco, S. [1 ]
Migliaccio, I. [1 ]
Cerchione, C. [2 ]
Catalano, L. [2 ]
Ferrara, K. [2 ]
Peluso, I. [2 ]
Monaco, G. [1 ]
Farina, G. [3 ]
Gagliardi, A. [4 ]
Barone, M. [5 ]
Esposito, D. [6 ]
Amico, V. [7 ]
Arcamone, M. [8 ]
Fontana, R. [9 ]
Sica, A. [10 ]
Pane, F. [2 ]
Ferrara, F. [1 ]
机构：
[1] AORN A Cardarelli, Ematol Unita TMO, Naples, Italy
[2] AUOP Federico II, Ematol, Naples, Italy
[3] AORN S Anna & S Sebastiano, UOC Oncoematol, Naples, Italy
[4] ASL Na1 Ctr, Osped Ascalesi, UOC Ematol, Naples, Italy
[5] PO A Tortora, UO Ematol Oncol, Naples, Italy
[6] Osped San Giuseppe Moscati, ASL CE, UOC Ematol, Statte, TA, Italy
[7] AORN G Rummo, DH Ematol, Benevento, Italy
[8] Fdn G Pascale IRCCS, UOSC Ematol Oncol, Naples, Italy
[9] AOU Ruggi dAragona, Ematol, Salerno, Italy
[10] AOU Vanvitelli, Oncol Med & Ematol, Naples, Italy
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P188
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [1] KRD (CARFILZOMIB PLUS LENALIDOMIDE PLUS DEXAMETHASONE) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A REAL LIFE SURVEY IN CAMPANIA REGION IN SOUTHERN ITALY
    Palmieri, S.
    Rocco, S.
    Migliaccio, I
    Cerchione, C.
    Catalano, L.
    Ferrara, K.
    Peluso, I
    Monaco, G.
    Farina, G.
    Gagliardi, A.
    Barone, M.
    Esposito, D.
    Amico, V
    Arcamone, M.
    Fontana, R.
    Sementa, A.
    Sica, A.
    Svanera, G.
    Pane, F.
    Ferrara, F.
    HAEMATOLOGICA, 2018, 103 : 36 - 37
  • [2] ECONOMIC EVALUATION OF CARFILZOMIB plus LENALIDOMIDE plus DEXAMETHASONE (KRD) VS LENALIDOMIDE plus DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R/RMM)
    Fonseca, R.
    Panjabi, S.
    Campioni, M.
    Giannopoulou, A.
    Benedict, A.
    Houisse, I.
    Aggarwal, S.
    Jakubowiak, A.
    HAEMATOLOGICA, 2016, 101 : 526 - 526
  • [3] Economic evaluation of carfilzomib plus lenalidomide plus dexamethasone (KRd) vs. lenalidomide plus dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
    Jakubowiak, Andrzej J.
    Benedict, Agnes
    Panjabi, Sumeet
    Houisse, Ivan
    Campioni, Marco
    Giannopoulou, Andromachi
    Aggarwal, Sanjay
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients
    Palmieri, Salvatore
    Rocco, S.
    Vitagliano, O.
    Catalano, L.
    Cerchione, C.
    Vincelli, I. D.
    Scopelliti, A.
    Gentile, M.
    Farina, G.
    Barone, M.
    Gagliardi, A.
    Esposite, D.
    Arcamone, M.
    Amico, V
    Fontana, R.
    Sementa, A.
    Sica, A.
    Svanera, G.
    Pane, F.
    Ferrara, F.
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2903 - 2909
  • [5] KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients
    Salvatore Palmieri
    S. Rocco
    O. Vitagliano
    L. Catalano
    C. Cerchione
    I. D. Vincelli
    A. Scopelliti
    M. Gentile
    G. Farina
    M. Barone
    A. Gagliardi
    D. Esposito
    M. Arcamone
    V. Amico
    R. Fontana
    A. Sementa
    A. Sica
    G. Svanera
    F. Pane
    F. Ferrara
    Annals of Hematology, 2020, 99 : 2903 - 2909
  • [6] Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Dabkara, Deepak
    Bajpai, Jyoti
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (03) : 10 - 13
  • [7] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Spencer, Andrew
    Attal, Michael
    Prince, H. Miles
    Harousseau, Jean-Luc
    Dmoszynska, Anna
    San Miguel, Jesus
    Hellmann, Andrzej
    Facon, Thierry
    Foa, Robin
    Corso, Alessandro
    Masliak, Zvenyslava
    Olesnyckyj, Marta
    Yu, Zhinuan
    Patin, John
    Zeldis, Jerome B.
    Knight, Robert D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) : 2123 - 2132
  • [8] Minimal residual disease assessment using EuroFlow in patients with relapsed/refractory multiple myeloma who received carfilzomib plus lenalidomide plus dexamethasone (KRD) therapy
    Takamatsu, Hiroyuki
    Yoroidaka, Takeshi
    Yamashita, Takeshi
    Murata, Ryoichi
    Yoshihara, Kyoko
    Yoshihara, Satoshi
    Ueda, Mikio
    Nakao, Shinji
    Matsue, Kosei
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E184 - E184
  • [9] TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN COLOMBIA
    van Beurden-Tan, C.
    Forero, J.
    Coggia, A.
    Bustos Marquez, M. C.
    VALUE IN HEALTH, 2019, 22 : S480 - S480
  • [10] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Pineiro, Luis
    Jakubowiak, Andrzej
    de Boer, Carla
    Wang, Jianping
    Clemens, Pamela L.
    Ukropec, Jon
    Schecter, Jordan
    Lonial, Sagar
    Moreau, Philippe
    BLOOD, 2019, 134 (05) : 421 - 431
12345